Hikma Pharmaceuticals PLC, the multinational pharmaceutical group (HIK, NASDAQ Dubai: HIK and HKMPY) today announced its financial results for the first half of the year. June 30, 2019. Group-wide revenue for Hikma was US $ 1,047 million, up 7% from US $ 979 million for the first half of 2018, reflecting strong sales of both market and newly launched products.
During the first half of 2019, the global revenues of the global pharmaceuticals sector increased by 4% to reach US $ 428 million, compared to US $ 410 million in the first half of 2018. In fixed currency, revenues of the global pharmaceuticals sector increased by 7%, Revenue in the MENA region increased by 18% to US $ 60 million compared to US $ 51 million in 1H2018, and fixed income to 20%, reflecting good performance across markets "Wisdom", especially in Saudi Arabia To Saudi Arabia and Egypt. It is now expected that the results of the drug sector will be higher than the average forecast last year.
Generic pharmaceutical revenues increased by 11% to US $ 368 million, compared to US $ 332 million in the first half of 2018, as price declines were offset by strong demand for the market's most premium products and new products. All. With good financial results for the first half of the year, Hikma raised the full-year forecast for generic pharmaceutical revenues and operating profit.
According to the financial reports, the revenues of the registered trademark sector reached US $ 242 million, an increase of 4% compared to the US $ 232 million in the first half of last year. On a fixed currency basis, revenue from the registered brand segment grew by 6% to US $ 246 million. In its largest markets, Saudi Arabia and Egypt, Al Hikma has achieved double-digit revenue growth, reflecting strong demand for the marketed products and newly launched products. Despite the decline in sales in Algeria due to the economic slowdown there, the strong performance achieved by "wisdom" in most of its markets in the Middle East and North Africa has compensated for this decline.